A New York judge on Friday gave final approval to Acorda Therapeutics' $60 million Chapter 11 financing package after hearing the drug...
1 day ago

After years of struggling with hurdles such as generic competition and significantly lower-than-expected sales of its top meds, Acorda...
4 weeks ago

Acorda Therapeutics becomes the latest biotechnology company in 2024 to go bankrupt and shutter its business, following years of financial...
1 month ago

The notice follows the Company's April 1, 2024 announcement that it has reached an agreement with Merz Therapeutics to acquire substantially all...
1 month ago

Pharmaceutical company says it has a 'stalking horse' bid for its assets ahead of an auction process ... Acorda Therapeutics said it filed for...
1 month ago

Acorda manufactures, AMPYRA, or FAMPYRA outside the U.S., their brand name for dalfampridine, a prescription medicine used to help improve...
4 weeks ago

Shares of Acorda Therapeutics fell late Monday after the company said it had filed for bankruptcy protection.
1 month ago

Westchester County issues warning regarding phony contractors ... Pearl River's Acorda Therapeutics, a developer of therapies for neurological...
4 weeks ago

Acorda Therapeutics stock is falling hard on Tuesday after the company announced a bankruptcy filing and stalking horse bid agreement.
1 month ago

Merz placed a “stalking horse bid” for Acorda's Parkinson's disease and multiple sclerosis treatments.
1 month ago